Literature DB >> 2143474

An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3.

A M Millar1, L M O'Brien.   

Abstract

Technetium 99m mercaptoacetyltriglycine (99mTc-MAG3) was prepared from a commercial kit by various techniques to assess the effect of a number of variables on radiochemical purity and stability. Its radiochemical purity was determined by high performance liquid chromatography at 0 and 6 h after preparation and was found to be consistently greater than 95%. It has been demonstrated that the radiochemical purity of 99mTc-MAG3 prepared according to the manufacturer's instructions is not influenced by the volume of 99mTc generator eluate used, agitation, the presence of air in the reaction vial or the use of a 99mTc generator eluate with a 99Tc:99mTc ratio of 16:1. A modified method of preparation in which the MAG3 kit is reconstituted with saline before addition of 99mTc-pertechnetate has been shown to yield a satisfactory product and should help to minimise the radiation dose to the fingers of radiopharmacy staff.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143474     DOI: 10.1007/bf00998158

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  Technetium-99m MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure.

Authors:  A Taylor; D Eshima; P E Christian; W W Wooten; L Hansen; K McElvany
Journal:  J Nucl Med       Date:  1988-05       Impact factor: 10.057

2.  Technetium-99m labeled renal function and imaging agents: II. Clinical evaluation of 99mTc MAG3 (99mTc mercaptoacetylglycylglycylglycine).

Authors:  B Bubeck; W Brandau; M Steinbächer; F Reinbold; K Dreikorn; M Eisenhut; P Georgi
Journal:  Int J Rad Appl Instrum B       Date:  1988

3.  Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders.

Authors:  R A Jafri; K E Britton; C C Nimmon; K Solanki; A Al-Nahhas; J Bomanji; J Fettich; L A Hawkins
Journal:  J Nucl Med       Date:  1988-02       Impact factor: 10.057

4.  Tc-generators - yield of 99mTc and ratio to 'inactive' 99Tc.

Authors:  R Bauer; H W Pabst
Journal:  Eur J Nucl Med       Date:  1982

5.  99Tcm-MAG3: in vitro stability and in vivo behaviour at different times after preparation.

Authors:  A M Millar; A G Wilkinson; E McAteer; J J Best
Journal:  Nucl Med Commun       Date:  1990-06       Impact factor: 1.690

6.  Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement.

Authors:  A R Fritzberg; S Kasina; D Eshima; D L Johnson
Journal:  J Nucl Med       Date:  1986-01       Impact factor: 10.057

7.  99mTc-MAG3, a new renal imaging agent: preliminary results in patients.

Authors:  A Taylor; D Eshima; N Alazraki
Journal:  Eur J Nucl Med       Date:  1987

8.  Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA.

Authors:  A A Al-Nahhas; R A Jafri; K E Britton; K Solanki; J Bomanji; S Mather; M A Carroll; M Al-Janabi; V Frusciante; B Ajdinowic
Journal:  Eur J Nucl Med       Date:  1988
  8 in total
  1 in total

1.  Comparison of technetium-99m MAG3 kit formulations in Europe and the USA.

Authors:  J C Hung
Journal:  Eur J Nucl Med       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.